CAR-T at a crossroad as industry looks to allogeneic
As cell therapies move through the clinic towards commercialization, respondents to a KNect365 industry survey are beginning to look to allogeneic – or off-the-shelf – products as the next big thing. Almost 200 people contributed to the Cell Therapy Analytics Report from KNect365, revealing t ...
Sartorius will add biomolecular characterization, chromatography hardware and resins, and microcarriers in the deal, dependent on the closure of ...
Danish drugmaker Genmab has upped its relationship with long-term CDMO partner Lonza by reserving space at the Ibex Design and Ibex Develop facil ...
Cobra Biologics will produce the AAV viral vector for Combigene’s epilepsy gene therapy from its facilities in Keele, UK.
Nordic gene therap ...
Process development (PD) is a vital CDMO function and one that Avid will continue to invest in, the firm says as it opens a multi-million-dollar ...
Recent Tweets
-
RT @Dan5tanton: CAR-T at a crossroads: As #celltherapies move through the clinic, industry is beginning to look to allogeneic say… https://t.co/pnISRznt1P
8 hours ago
-
RT @Dan5tanton: Sanofi Genzyme has completed process qualification runs at a plant in Framingham based on digital and continuous bi… https://t.co/MpTBA5IxKk
6 days ago
-
RT @Dan5tanton: Lonza CEO Marc Funk says the #CDMO will take a pragmatic approach to expanding its position from "timid actor" to m… https://t.co/U82uduWDoM
1 week ago
-
RT @BioProcessIntl: The New Era of Emerging Therapies Webinar Series
Oct. 29-30 presented by @Xconomy
CRISPR in t… https://t.co/1AKlSbPLbC
2 weeks ago
Trending
Upstream Processing
eBook: Bioreactor Scale-Up: From Pilot to Commercial Scale in the Modern Era
Manufacturing
eBook: Autologous Cell Therapies: Commercialization Strategies
Ask the Experts
Scalable Purification Strategies for Viral Vectors and Vaccines
Analytical
Introduction: Reporting from the Frontiers of Cell Line Engineering at BPI Europe and BPI West